Answers are grounded in this paper and cite their sources.
BACKGROUND: Generalized demodicosis is a severe skin disease in the dog, with limited treatment options. HYPOTHESIS/OBJECTIVES: To demonstrate that doramectin, when given at a dose rate of 0.6 mg/kg body weight, is a safe and effective treatment for generalized demodicosis in the dog. ANIMALS: Four hundred client-owned dogs diagnosed with generalized demodicosis at one general small-animal practice. Of these, 232 completed their treatment and were included in the study. METHODS: A retrospective study was carried out by searching the computerised medical records of dogs seen at one general small-animal practice in Tennessee, USA. The records of each dog with a diagnosis of generalized demodicosis, who underwent treatment using weekly injections of doramectin at a dose rate of 0.6 mg/kg body weight, were analysed. RESULTS: Remission was achieved in 94.8% of dogs treated with weekly subcutaneous injections of doramectin at a dose rate of 0.6 mg/kg body weight. Adverse events were rare with two suspected instances (0.5%) being recorded. The mean duration of treatment was 7.1 weeks. CONCLUSIONS AND CLINICAL IMPORTANCE: Doramectin given at a dose rate of 0.6 mg/kg body weight by subcutaneous injection at weekly intervals is a useful and well-tolerated treatment for generalized demodicosis in the dog.
No takes yet. Share an insight, caveat, or question.
Hutt et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: